Cambridge Heart Inc. announced that it has reached an agreement in principle with St. Jude Medical Inc. to amend its co-marketing agreement with St. Jude Medical to a non-exclusive arrangement, which will enable Cambridge Heart to move forward with the new placement program. Under the new arrangement Cambridge Heart assumes complete sales responsibility. Cambridge Heart will continue to work with the St. Jude Medical field sales force to market MTWA technology, support existing customers and identify new opportunities.

Cambridge Heart Inc. reported total revenue of $1,176,601 for the first quarter ended March 31, 2008, a decrease of 55% from total revenue of $2,589,519 reported during the same period of 2007. The operating loss for the first quarter of 2008 was $2,548,563, compared to an operating loss of $3,252,905 for the same period in 2007. Included in the operating loss for the first quarter of 2008 was $742,987 of non-cash stock-based compensation expense. The net loss for the quarter was $2,382,600, or $0.04 per share, compared to a net loss of $3,155,855, or $0.05 per share, in the comparable 2007 period. Revenue for the first quarter from the sale of the Company´s Microvolt T-Wave Alternans products was $978,465, a decrease of 58% compared with the same period in 2007. Sequentially, in the first quarter of 2008 sales from the Company´s Alternans products decreased 49% from the fourth quarter of 2007.

Cambridge Heart Inc., Q1 2008 Earnings/Operating Results Call, May-07-2008